<DOC>
	<DOCNO>NCT00489385</DOCNO>
	<brief_summary>This study determine Albumin-linked interferon ( Albinterferon alfa-2b ) every 2 week safe tolerate patient infected hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) . This new medication develop HCV . It may help immune system fight infection , especially caused virus . Albinterferon alfa-2b appear quite similar interferon , side effect action control HCV . Patients age 18 older infect HCV genotype 1 , HIV positive , infected HCV , evidence HCV-induced liver disease ; pregnant breast feeding may eligible study . Many visit NIH 76-week period require . There collection blood urine , pregnancy test , test HCV blood . A liver biopsy require start study patient one within 1 year . Another do end 72 week . An eye exam do start study repeat later . An optional procedure call automate pheresis do study begin . Researchers study patient ' immunity control HCV . Blood drawn needle arm vein spin machine separate desire blood component . Remaining blood return patient . Patients receive Albinterferon alfa-2b dose 900 mcg every 2 week 48 week , injection skin . Ribavirin give 1,000 mg 1,200 mg mouth twice daily , depend patient 's weight . Side effect Albinterferon alfa-2b fatigue , headache , joint muscle pain , sleeplessness . The major side effect ribavirin anemia . Visits range week 3 44 determine safety Albinterferon alfa-2b ribavirin see effect reduce HCV viral load . For week 48 , 52 , 56 , 64 , 72 , 76 , patient return clinic visit blood test . At week 72 , abdominal ultrasound liver biopsy do . Week 76 include discussion biopsy result .</brief_summary>
	<brief_title>An Open Label Non-Randomized Dose Escalating Trial Assess Safety Tolerability Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals</brief_title>
	<detailed_description>Hepatitis C infection occur one-third human immunodeficiency virus ( HIV ) -infected individual . Liver disease become significant among subject coinfected HIV hepatitis C virus ( HCV ) . Several study show coinfected individual develop earlier severe liver disease . Pegylated interferon alpha ribavirin ( RBV ) become therapy choice HCV among people HCV alone . However , pegylated interferon RBV therapy HIV/HCV coinfected subject result modest cure rate . This open-label , non-randomized prospective trial ass safety tolerability Alb-IFN ( interferon alpha genetically fuse human serum albumin ) 900 mcg every 2 week ( Q2w ) daily RBV among HIV/HCV coinfected individual . Twenty-five subject infect HIV HCV also evidence chronic hepatitis , na anti-HCV treatment , receive Alb-IFN 900 mcg Q2w together standard daily dose RBV 48 week . These subject monitor Alb-IFN serum concentration level , HCV viral load , HIV viral load , CD4 count , undergo baseline liver biopsy another optional liver biopsy end 72 week . The result study enable u good delineate efficacy Alb-IFN suppressing hepatitis C virus HIV/HCV coinfected subject . This important give current low cure rate HCV among HIV coinfected individual .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Age great equal 18 year . 2 . Documentation HIV1 infection license ELISA test confirm Western Blot . 3 . Documentation hepatitis C infection demonstration positive test hepatitis C antibody HCV RNA level 2000 copies/mL great . 4 . Histopathologic feature consistent chronic hepatitis C time enrollment . A liver biopsy do subject within 24 month prior participation may use baseline biopsy . 5 . Patients infect genotype 1 . 6 . Patients CD4+ cell count great 100 cells/mm ( 3 ) . 7 . Ability sign Informed Consent document , willingness comply study requirement clinic policy . 8 . Neutrophil count great 1000 cells/mm ( 3 ) . 9 . Platelets great 75,000/mm ( 3 ) . 10 . Hemoglobin great 10.5 g/dL . 11 . ALT less 7 time NIH upper limit normal . 12 . Serum lipase less 1.5 time NIH upper limit normal . 13 . Not pregnant breastfeeding . 14 . If patient able become pregnant , must use two effective method contraception study . Effective contraceptive method include abstinence , surgical sterilization either partner , barrier method diaphragm , condom , cap , sponge , use hormonal contraception antiHIV regimen alter metabolism hormonal contraception . This advised basis use ribavirin , may potential teratogenic effect fetus pregnant woman . 15 . Willingness become pregnant 7 month completion ribavirin therapy . 16 . Male subject document sterile agree either abstain intercourse consistently correctly use condom female partner ( applicable ) agree use one appropriate medically accept method birth control list date screen 7 month last dose ribavirin . 17 . Patients documented addiction currently addictionfree period least 6 month clinical judgment investigator risk relapse . 18 . Opioiddependent patient supervise methadone treatment program . 19 . Need primary doctor outside OP8 part OP8 training clinic take care patient HIV infection liver disease . 20 . Willing designate person durable power attorney NIH form medical research medical care purpose NIH Clinical Center . 21 . Able learn safely inject medication AlbIFN subcutaneously able find another person clinic inject medication him/her . 22 . Willingness abstain alcohol use trial . 23 . Willingness allow store blood tissue sample use future study HIV disease immune function . 24 . Willingness permit HLA typing perform . EXCLUSION CRITERIA : 1 . Patient experimental therapy ( include expand access/compassionate use antiretrovirals ) his/her participation protocol . 2 . Patients use interferon peginterferon previously treatment hepatitis C. 3 . Mixed genotype ( e.g. , 1/2 , 1/4 ) . Mixed genotype 1a/1b enrol . 4 . Liver histology , opinion Clinical Center pathologist , consistent coexistent cause chronic liver disease define : chronic hepatitis B positive HBsAg autoimmune hepatitis positive ANA great 1 unit positive anti mitochondrial antibody great 1 unit ; cholestatic disease persistent elevation alkaline phosphatase ; primary biliary cirrhosis sclerosing cholangitis ; Wilson 's disease ; alpha1antitrypsin deficiency ; steatohepatitis ( alcoholic non alcoholic ) mark steatosis , many Mallory body , extensive zone 3 periportal fibrosis . 5 . Hemochromatosis secondary iron overload define ( 1 ) elevate serum ferritin iron saturation ( serum iron/IBC time 100 % ) great 50 % , ( 2 ) presence 3+ stainable iron liver biopsy accord study pathologist . Those subject , history previous phlebotomy iron overload undergo HFE genetic counseling positive HFE genetic test demonstrating homozygosity C282Y H63D eligible . Those compound heterozygosity C282Y H63D also eligible . 6 . For patient cirrhosis , Child Turcotte Pugh score great 7 . 7 . PTINR great 2 history hemophilia know history Vitamin K deficiency use anticoagulant . 8 . Organ transplant recipient cornea hair transplant . 9 . Estimated Creatinine clearance ( eGFR ) less 50 mL/min . 10 . A serum alphafetoprotein level ( great 20 ng/mL , unless subject negative ultrasound enrollment . 11 . For patient history diabetes mellitus , HbA1C le equal 7.5 % fast blood glucose level great 140mg/dL , HbA1C le equal 7.5 % . 12 . Coexisting neoplastic disease except Kaposi 's sarcoma , nonmetastatic skin cancer resect , nonmetastatic cervical anal cancer resect . 13 . Severe cardiac disease ( Grade 3 congestive cardiac failure , symptomatic coronary artery disease , significant arrhythmia , uncontrolled hypertension ) . 14 . Severe chronic pulmonary disease functional impairment DLCO le equal 50 % baseline . 15 . Severe psychiatric disorder would interfere adherence protocol requirement . 16 . Preexisting autoimmune disorder include inflammatory bowel disease , psoriasis , optic neuritis . 17 . Preexisting uncontrolled seizure disorder define one episode seizure within past 2 year . 18 . Chronic pancreatitis . 19 . Severe retinopathy determine ophthalmologist . 20 . Hemoglobinopathy ( e.g. , Thalassemia , sickle cell disease ) . 21 . Currently take didanosine d4T part antiretroviral regimen . 22 . Direct bilirubin great equal 0.6 mg/dL . 23 . Concurrent use immunosuppressive therapy , include systemic steroid ( prednisone equivalent great 10 mg/day ) duration six week within six month prior enrollment . 24 . Concurrent use fluticasone high dose ritonavir ( 600mg t.i.d ) . 25 . Chronic viral hepatitis etiology hepatitis C. 26 . Active systemic infection hepatitis C HIV . 27 . Liver disease cause reason hepatitis C , like HBV , HDV , Wilson 's disease , hemochromatosis , autoimmune hepatitis ( ANA great 1 unit ) except history drugassociated hepatitis discontinuation causative agent . 28 . Hepatic mass suggestive hepatocellular carcinoma detect ultrasound scan . 29 . Alcohol substance abuse within past 6 month potentially could interfere patient compliance . 30 . Concomitant use amphetamine , barbiturate , cocaine , ganciclovir , isoniazid , opiates , pyrazinamide , rifabutin , rifampin/rifampicin , thalidomide , theophylline . 31 . History esophageal varix . 32 . Any systemic illness make unlikely subject able return NIH require study visit . 33 . Evidence gastrointestinal malabsorption , chronic nausea , vomit . 34 . Male partner pregnant woman . 35 . Pregnant woman . 36 . Breastfeeding woman . 37 . Hypersensitivity interferon product ribavirin . 38 . Received silymarin ( milk thistle ) glycyrrhizin within 28 day prior Day 0 . 39 . Received Shosaikoto ( SST ) within 28 day prior Day 0 . 40 . Received experimental agent within 28 day prior Day 0 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 25, 2012</verification_date>
	<keyword>Fibrosis</keyword>
	<keyword>Viral Kinetics</keyword>
	<keyword>Hepatotoxicity</keyword>
	<keyword>Immunity</keyword>
	<keyword>HIV Infection</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>